Pharmaceutical Company CEO Developing $100 Alternative To EpiPen After 'Shameful' Price Hike
September 4, 2016
Mark Baum, CEO of Imprimis Pharmaceuticals who previously came out with a $1 alternative to Martin Shkreli's AIDS drug after 5000% price hike, is now going to take on Mylan and is plotting to offer a $100 EpiPen alternative.

Mark Baum / Imprimis Pharmceuticals
Baum believes the relentless EpiPen price hikes are "shameful" and plans to have a compounded version of the allergy treatment by the end of the year.
"I don't need to make $19 million a year," Baum said, referring to the big pay package Mylan's CEO Heather Bresch took home last year.
"Tonight when I go home I'm going to eat a nice piece of fish and the fish I eat isn't any better or worse than what she is going to eat."
His Last Day As A Teacher After 36 Years. They Turned It Into A Memory For Life
Mailman Shares All The Adorable Snowmen Found On Her Route This Winter
Meet Despereaux, The Adorable Dumbo Mouse You’ll Want To See
Kids Are Loving The Tiny Duck Libraries Popping Up Around New York City
'I Laughed And Cried': Vet’s Hilarious Condolence Card Brings Laughter To Grieving Cat Owner
Teen Runs His Own Restaurant ALONE — One Of The Most Uplifting Stories You'll Read
Unexpected Friends: Rhino And Tiny Deer Play In Snow
Sheep Escape Herd And Wander Into Supermarket In Funny Video
Donkey Gets Tricked Into Taking His Medicine — And It’s Adorable
Kissing Rescue Dogs And Filming Their Reactions
I Picked Up My Sister From Work At A Doggy Daycare — Then This Happened
